Drug-Induced Interstitial Lung Disease
Drug-induced interstitial lung disease (DIILD) represents a rare but potentially fatal adverse drug reaction. A large number of drugs have been implicated to have this potential risk, including chemotherapeutics and disease-modifying antirheumatic drugs. The clinical presentations, laboratory invest...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=19;epage=26;aulast=Lee |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849304276464041984 |
|---|---|
| author | Wei-I Lee Pravin Hissaria |
| author_facet | Wei-I Lee Pravin Hissaria |
| author_sort | Wei-I Lee |
| collection | DOAJ |
| description | Drug-induced interstitial lung disease (DIILD) represents a rare but potentially fatal adverse drug reaction. A large number of drugs have been implicated to have this potential risk, including chemotherapeutics and disease-modifying antirheumatic drugs. The clinical presentations, laboratory investigations, pulmonary function test result, and imaging and histopathological findings associated with drug-induced pulmonary fibrosis are nonspecific. The diagnosis is achieved after the exclusion of alternative diagnosis, such as infection, pulmonary edema, and connective tissue diseases. However, sometimes, the underlying diseases (e.g., rheumatoid arthritis) and the drugs used to treat the disease (e.g., methotrexate) can both cause ILD; it is often difficult to tease out causality especially if baseline pulmonary assessment (respiratory function test and imaging) is incomplete prior to the commencement of the drug therapy. Many efforts have been put into investigating the pathogenesis of the DIILD, particularly as animal model of bleomycin-induced pulmonary fibrosis has been used as a surrogate for idiopathic pulmonary fibrosis. However, more research is required to improve our understanding of pathogenesis in order to develop more sensitive and specific diagnostic tests as well as to establish evidence-based treatment approach. |
| format | Article |
| id | doaj-art-198e8673a62844bcb794c5e1738e17d1 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-198e8673a62844bcb794c5e1738e17d12025-08-20T03:55:48ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012019-01-01145192610.4103/0973-3698.272161Drug-Induced Interstitial Lung DiseaseWei-I LeePravin HissariaDrug-induced interstitial lung disease (DIILD) represents a rare but potentially fatal adverse drug reaction. A large number of drugs have been implicated to have this potential risk, including chemotherapeutics and disease-modifying antirheumatic drugs. The clinical presentations, laboratory investigations, pulmonary function test result, and imaging and histopathological findings associated with drug-induced pulmonary fibrosis are nonspecific. The diagnosis is achieved after the exclusion of alternative diagnosis, such as infection, pulmonary edema, and connective tissue diseases. However, sometimes, the underlying diseases (e.g., rheumatoid arthritis) and the drugs used to treat the disease (e.g., methotrexate) can both cause ILD; it is often difficult to tease out causality especially if baseline pulmonary assessment (respiratory function test and imaging) is incomplete prior to the commencement of the drug therapy. Many efforts have been put into investigating the pathogenesis of the DIILD, particularly as animal model of bleomycin-induced pulmonary fibrosis has been used as a surrogate for idiopathic pulmonary fibrosis. However, more research is required to improve our understanding of pathogenesis in order to develop more sensitive and specific diagnostic tests as well as to establish evidence-based treatment approach.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=19;epage=26;aulast=Leedrug-inducedinterstitial lung diseasepulmonary fibrosis |
| spellingShingle | Wei-I Lee Pravin Hissaria Drug-Induced Interstitial Lung Disease Indian Journal of Rheumatology drug-induced interstitial lung disease pulmonary fibrosis |
| title | Drug-Induced Interstitial Lung Disease |
| title_full | Drug-Induced Interstitial Lung Disease |
| title_fullStr | Drug-Induced Interstitial Lung Disease |
| title_full_unstemmed | Drug-Induced Interstitial Lung Disease |
| title_short | Drug-Induced Interstitial Lung Disease |
| title_sort | drug induced interstitial lung disease |
| topic | drug-induced interstitial lung disease pulmonary fibrosis |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=19;epage=26;aulast=Lee |
| work_keys_str_mv | AT weiilee druginducedinterstitiallungdisease AT pravinhissaria druginducedinterstitiallungdisease |